A Phase 3 interventional study of bevacizumab [Avastin] and XELOX in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 7 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-09-18.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing xelox in Colorectal Neoplasms — 12 open to participants now, 12 under way, none of them phase 3. xelox · Colorectal Neoplasms.
Among the 19 studies testing xelox in Colorectal Neoplasms, this one is the 9th largest by enrollment, is one of 3 that started in 2006, is one of 2 in phase 3, and was the 1st registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →12 of the 19 studies testing xelox in Colorectal Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–75
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18–75
Hua Jiang · Sites in China
Ages 18–75
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Sites in China
Ages 18–80
Hansoh BioMedical R&D Company · Sites in China
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 3
First in 2006; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 54 across the 19 interventional studies. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 19 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
111 studies in Colorectal Neoplasms by Hoffmann-La Roche: 3 open now, 7 under way, none of them phase 3. Of 99 finished, 52 (53%) have results posted.
Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 45th largest by enrollment of the 77 interventional ones that give a count, is one of 8 that started in 2006, is one of 15 in phase 3, and was the 17th registered.
Hoffmann-La Roche’s Colorectal Neoplasms studies by the year they started, since 1998.
6 of the studies testing xelox in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07233850Shenyang Sunshine Pharmaceutical Co., LTD.A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | 2026-12 |
| NCT07007728Peking University Cancer Hospital & InstituteIparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis | 2026-12-31 |
| NCT07229846Yanqiao ZhangA Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | 2027-02 |
| NCT06835179The First Affiliated Hospital with Nanjing Medical UniversitySBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer. | 2027-02 |
| NCT06801665Hua JiangFMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis | 2027-02-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 19 studies testing xelox in Colorectal Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 111 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This 2 arm study will compare the pharmacokinetics and safety of Avastin at steady state under 2 different dosing regimens, in combination with XELOX (oxaliplatin + Xeloda) or FOLFOX-4 (oxaliplatin, leucovorin and 5-fluorouracil). Patients randomized to the XELOX arm will receive Avastin (7.5mg/kg iv) on Day 1 of each 3 week cycle; patients randomized to the FOLFOX-4 arm will receive Avastin (5mg/kg iv) on Day 1 of each 2 week cycle. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: bevacizumab [Avastin] · Drug: XELOX
Drug: bevacizumab [Avastin] · Drug: FOLFOX-4
7.5mg/kg iv on day 1 of each 3 week cycle
As prescribed
5mg/kg iv on day 1 of each 2 week cycle
As prescribed
Weekly Steady-state Exposure of Bevacizumab
Area under the serum concentration-time curve per week, at steady state (AUCss per week). Estimation of the parameter was performed using non-compartmental methods.
Time frame: Up to 48 weeks
Time Zero to Last Measurable Plasma Concentration of Bevacizumab
Area under the serum concentration-time curve from time zero to the time of the last measurable plasma concentration (AUC 0-last). Estimation of the parameter was performed using non-compartmental methods.
Time frame: Up to 48 weeks
Steady-state Exposure of Bevacizumab From Time Zero to Tau
Area under the serum concentration-time curve from time zero to tau, at steady state (AUCss 0-tau), where tau was the length of the cycle, i.e., tau = 3 weeks for XELOX+BV and tau = 2 weeks for FOLFOX-4+BEV. Estimation of the parameter was performed using non-compartmental methods.
Time frame: Up to 48 weeks
Maximum Serum Concentration of Bevacizumab at Steady State
Maximum serum concentration at steady state (Css,max). Estimation of the parameter was performed using non-compartmental methods.
Time frame: Up to 48 weeks
Minimum Serum Concentration of Bevacizumab at Steady State
Minimum serum concentration at steady state (Css, min). Estimation of the parameter was performed using non-compartmental methods.
Time frame: Up to 48 weeks
Serum Clearance of Bevacizumab
Serum clearance (CL). Estimation of the parameter was performed using non-compartmental methods.
Time frame: Up to 48 weeks
Time of Maximum Serum Concentration of Bevacizumab
Time of maximum serum concentration (tmax). Estimation of the parameter was performed using non-compartmental methods.
Time frame: Up to 48 weeks
Volume of Distribution of Bevacizumab at Steady State
Volume of distribution at steady state (Vss). Estimation of the parameter was performed using non-compartmental methods.
Time frame: Up to 48 weeks
Terminal Half-life of Bevacizumab
Terminal half-life (t1/2) (apparent elimination half-life). Estimation of the parameter was performed using non-compartmental methods.
Time frame: Up to 48 weeks
A total of 64 patients in 7 centers were enrolled between 01 August 2006 to 28 May 2008. 37 were included in the pharmacokinetic (PK) analyses.
| Milestone | XELOX+Bevacizumab | FOLFOX-4+Bevacizumab |
|---|---|---|
| Started | 32 | 32 |
| Completed | 19 | 18 |
| Not completed | 13 | 14 |
Area under the serum concentration-time curve from time zero to the time of the last measurable plasma concentration (AUC 0-last). Estimation of the parameter was performed using non-compartmental methods.
| day*ug/mL | XELOX+Bevacizumab | FOLFOX-4+Bevacizumab |
|---|---|---|
| Time Zero to Last Measurable Plasma Concentration of Bevacizumab | 2457.19 ± 359.5 | 1709.8 ± 497.0 |
Area under the serum concentration-time curve per week, at steady state (AUCss per week). Estimation of the parameter was performed using non-compartmental methods.
| day*ug/mL | XELOX+Bevacizumab | FOLFOX-4+Bevacizumab |
|---|---|---|
| Weekly Steady-state Exposure of Bevacizumab | 4090.3 ± 1047.6 | 4022.4 ± 1774.2 |
Area under the serum concentration-time curve from time zero to tau, at steady state (AUCss 0-tau), where tau was the length of the cycle, i.e., tau = 3 weeks for XELOX+BV and tau = 2 weeks for FOLFOX-4+BEV. Estimation of the parameter was performed using non-compartmental methods.
| day*ug/mL | XELOX+Bevacizumab | FOLFOX-4+Bevacizumab |
|---|---|---|
| Steady-state Exposure of Bevacizumab From Time Zero to Tau | 2457.0 ± 360.6 | 1758.4 ± 468.5 |
Maximum serum concentration at steady state (Css,max). Estimation of the parameter was performed using non-compartmental methods.
| ug/mL | XELOX+Bevacizumab | FOLFOX-4+Bevacizumab |
|---|---|---|
| Maximum Serum Concentration of Bevacizumab at Steady State | 242 ± 31.6 | 215.6 ± 53.2 |
Minimum serum concentration at steady state (Css, min). Estimation of the parameter was performed using non-compartmental methods.
| ug/ml | XELOX+Bevacizumab | FOLFOX-4+Bevacizumab |
|---|---|---|
| Minimum Serum Concentration of Bevacizumab at Steady State | 59.6 ± 14.1 | 80.0 ± 25.5 |
Serum clearance (CL). Estimation of the parameter was performed using non-compartmental methods.
| L/day | XELOX+Bevacizumab | FOLFOX-4+Bevacizumab |
|---|---|---|
| Serum Clearance of Bevacizumab | 0.236 ± 0.051 | 0.226 ± 0.056 |
Time of maximum serum concentration (tmax). Estimation of the parameter was performed using non-compartmental methods.
| hr | XELOX+Bevacizumab | FOLFOX-4+Bevacizumab |
|---|---|---|
| Time of Maximum Serum Concentration of Bevacizumab | 6.442 ± 6.786 | 4.958 ± 3.596 |
Volume of distribution at steady state (Vss). Estimation of the parameter was performed using non-compartmental methods.
| L | XELOX+Bevacizumab | FOLFOX-4+Bevacizumab |
|---|---|---|
| Volume of Distribution of Bevacizumab at Steady State | 4.932 ± 1.409 | 4.908 ± 1.563 |
Terminal half-life (t1/2) (apparent elimination half-life). Estimation of the parameter was performed using non-compartmental methods.
| hr | XELOX+Bevacizumab | FOLFOX-4+Bevacizumab |
|---|---|---|
| Terminal Half-life of Bevacizumab | 381.2 ± 91.7 | 394.1 ± 121.8 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| XELOX+Bevacizumab | — | 9/32 (28.1%) | 32/32 (100%) |
| FOLFOX-4+Bevacizumab | — | 15/32 (46.9%) | 32/32 (100%) |
| Event | XELOX+Bevacizumab | FOLFOX-4+Bevacizumab |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 4/32 | 1/32 |
| Abdominal PainGastrointestinal disorders | 0/32 | 2/32 |
| FatigueGeneral disorders | 0/32 | 2/32 |
| DehydrationMetabolism and nutrition disorders | 2/32 | 0/32 |
| HypersensitivityImmune system disorders | 0/32 | 2/32 |
| VomitingGastrointestinal disorders | 1/32 | 1/32 |
| Gastrointestinal ObstructionGastrointestinal disorders | 0/32 | 1/32 |
| IleusGastrointestinal disorders | 1/32 | 0/32 |
| NauseaGastrointestinal disorders | 0/32 | 1/32 |
| OesophagitisGastrointestinal disorders | 1/32 | 0/32 |
| Event | XELOX+Bevacizumab | FOLFOX-4+Bevacizumab |
|---|---|---|
| NauseaGastrointestinal disorders | 26/32 | 16/32 |
| FatigueGeneral disorders | 24/32 | 23/32 |
| DiarrhoeaGastrointestinal disorders | 20/32 | 23/32 |
| Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders | 18/32 | 1/32 |
| Peripheral Sensory NeuropathyNervous system disorders | 15/32 | 16/32 |
| AnorexiaMetabolism and nutrition disorders | 16/32 | 8/32 |
| Temperature IntoleranceGeneral disorders | 15/32 | 12/32 |
| Neuropathy PeripheralNervous system disorders | 15/32 | 15/32 |
| NeutropeniaBlood and lymphatic system disorders | 4/32 | 14/32 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 7/32 | 13/32 |
| Age Continuous(years) | XELOX+Bevacizumab | FOLFOX-4+Bevacizumab | Total |
|---|---|---|---|
| Mean | 55.9 ± 12.56 | 57.9 ± 10.84 | 56.9 ± 11.74 |
| Sex: Female, Male(Participants) | XELOX+Bevacizumab | FOLFOX-4+Bevacizumab | Total |
|---|---|---|---|
| Female | 13 | 17 | 30 |
| Male | 19 | 15 | 34 |
The record gives a start of Aug 2006, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Xelox